CORCEPT THERAPEUTICS INC cotiza a 117.80 USD y tiene una capitalización bursátil de $12.7B. En los últimos 12 meses ha facturado $831M con un margen de flujo de caja libre del 18.6%. Cotiza a 119.1 veces su flujo de caja libre (P/FCF) y a un PER de 230.8. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hyper…
| Periodo | 2026-11 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.36 | $-0.30 | $0.20 |
| Estimado | $0.85 | $0.06 | $-0.14 | $0.33 |
| Sorpresa | — | +500.0% | -114.3% | -39.4% |
| Métrica | CORT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 98.3% | 57.0% | +41.3% |
| Operating Margin | 5.9% | -38.6% | +44.5% |
| Net Margin | 13.1% | -33.6% | +46.7% |
| FCF Margin | 18.6% | -13.9% | +32.5% |
| ROE | 15.4% | -40.4% | +55.8% |
| ROA | 11.9% | -32.0% | +43.9% |
| Current Ratio | 2.92 | 2.84 | +0.08 |
| Debt / Equity | — | 0.28 | — |